Cochrane · systematic review · CD012462
Nasal decontamination for the prevention of surgical site infection in Staphylococcus aureus carriers
Liu, Z, Norman, G, Iheozor‐Ejiofor, Z, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
WoundsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 33.3%Very low 1 · 16.7%Low 3 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Mupirocin compared with placebo for the prevention of surgical site infection in Staphylococcus aureus carriers
Population: S aureus carriers undergoing cardiac surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
SSI Mupirocin vs placebo | RR 1.6 [0.79, 3.25] | 1 study · 257 participants | Low Downgraded: imprecision |
S aureus SSI Mupirocin vs placebo | RR 1.22 [0.34, 4.44] | 1 study · 257 participants | Low Downgraded: imprecision |
Mortality Mupirocin vs placebo | RR 0.78 [0.21, 2.84] | 1 study · 257 participants | Low Downgraded: imprecision |
Adverse events Mupirocin vs placebo | no estimate extracted | 1 study · 257 participants | Ungraded |
Anerdian compared with no treatment for the prevention of surgical site infection in Staphylococcus aureus carriers
Population: S aureus carriers undergoing cardiac surgery
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
SSI Anerdian vs no treatment | RR 0.89 [0.06, 13.08] | 1 study · 34 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Anerdian vs no treatment | no estimate extracted | 1 study · 34 participants | Ungraded |